Industry

Isotopia to supply its medical radioisotope, lutetium-177, for the clinical development of Clovis Oncology’s targeted radionuclide therapy candidate FAP-2286 BOULDER, Colo. & PETACH TIKVA, Israel–(BUSINESS WIRE)–$CLVS—Clovis Oncology, Inc. (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd. today announced the signing of a clinical supply agreement that provides Clovis Oncology with Isotopia’s lutetium-177 (177Lu) n.c.a. for use … [Read more…]

Combining the power of spatial biology and AI, Propath and Nucleai push the boundaries of pathology tissue analytics to develop a novel, high multiplexed immunofluorescence (IF) panel and associated AI-powered algorithm for biomarker discovery and development HEREFORD, United Kingdom & TEL AVIV, Israel–(BUSINESS WIRE)–#aipowered—Propath UK, Europe’s leading CRO for spatial biology, and Nucleai, a leader … [Read more…]

SAB comprised of leading experts in ophthalmology to provide strategic support for the advancement of Azura’s first-in-class Ophthalmic Keratolytics TEL AVIV, Israel & MELBOURNE, Australia–(BUSINESS WIRE)–Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced the formation of its scientific advisory board (SAB), comprised … [Read more…]

MALVERN, Pa.–(BUSINESS WIRE)–Alliance Pharma (Alliance), a global leader in bioanalytical, DMPK and CMC testing services in the pharmaceutical and biopharmaceutical industry, has grown their leadership team by four, bringing on board a new Chief Operating Officer (COO), Chief Commercial Officer (CCO), Chief Financial Officer (CFO), and Chief People Officer (CPO). These leaders will support continued … [Read more…]

VANCOUVER, British Columbia–(BUSINESS WIRE)–$ABCL—AbCellera (Nasdaq: ABCL) today announced it has launched the second phase of its global headquarters expansion by breaking ground on its new facility in Vancouver, Canada. The 380,000-square-foot tech campus will include state-of-the-art lab and office spaces to support AbCellera’s capabilities in bringing new antibody-based medicines from target to the clinic. The … [Read more…]

This new partnership brings high-resolution, single-cell whole genome and whole transcriptome analysis to Europe. This partnership will enable novel insights and deep cellular characterization required in the evaluation, creation, and validation of new generation biologics and therapeutics in targeted disease management. DURHAM, N.C. & AARHUS, Denmark–(BUSINESS WIRE)–#CRISPR—BioSkryb Genomics, a pioneer in developing scientifically advanced single-cell … [Read more…]

Hologic Global Women’s Health Index finds widespread barriers to preventive care and a growing gap in women’s well-being between high- and low-income countries MARLBOROUGH, Mass.–(BUSINESS WIRE)–$HOLX #Gallup–More than 1.5 billion women worldwide lack screenings for cancer, heart disease, diabetes or sexually transmitted diseases/infections – even though these conditions together affect billions of women. The finding … [Read more…]

NERVIANO, Italy–(BUSINESS WIRE)–Nerviano Medical Sciences S.r.l. (NMS), a member of the NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, announced today the signing of a collaboration agreement with licensing option with Merck Healthcare KGaA (Merck), for the next-generation highly selective and brain penetrant PARP1 inhibitor NMS-293. … [Read more…]

Not intended for UK- or Canada-based media NMS-293 is a next generation, orally available, brain-penetrant PARP1 selective inhibitor NMS-293 is currently studied in Phase I as monotherapy for the treatment of patients with BRCA-mutated tumors and in combination with temozolomide in recurrent glioblastoma Next generation PARP1 selective inhibitors could fill a significant unmet patient need … [Read more…]

Not intended for US-, Canada- or UK-based media NMS-293 is a next generation, orally available, brain-penetrant PARP1 selective inhibitor NMS-293 is currently studied in Phase I as monotherapy for the treatment of patients with BRCA-mutated tumors and in combination with temozolomide in recurrent glioblastoma Next generation PARP1 selective inhibitors could fill a significant unmet patient … [Read more…]